<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03629223</url>
  </required_header>
  <id_info>
    <org_study_id>MS200095_0044</org_study_id>
    <secondary_id>2017-005056-29</secondary_id>
    <nct_id>NCT03629223</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Tablet Formulation 3 (TF3) and Tablet Formulation 2 (TF2) and Effect of Food on the Pharmacokinetics (PK) of Tepotinib</brief_title>
  <official_title>Phase 1, Open-label, 3-Parts Study With Crossover Design in Each Part to Investigate the Bioequivalence of the Tablet Formulation of Tepotinib TF3 Compared to TF2 (Part A), and to Investigate the Influence of Food on the Pharmacokinetics of Each Tablet Formulation TF2 (Part B) and TF3 (Part C) of Tepotinib in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will demonstrate bioequivalence between the new tablet formulation (TF3, test
      treatment) and the tablet formulation used in clinical studies (TF2, reference treatment) and
      will investigate effect of food on PK of tepotinib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 23, 2018</start_date>
  <completion_date type="Actual">January 25, 2019</completion_date>
  <primary_completion_date type="Actual">January 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC 0-t) of Tepotinib</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Tepotinib</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Maximum Observed Plasma Concentration (Cmax) of Tepotinib</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC 0-t) of Tepotinib</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Tepotinib</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Maximum Observed Plasma Concentration (Cmax) of Tepotinib</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC 0-t) of Tepotinib</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Tepotinib</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C: Maximum Observed Plasma Concentration (Cmax) of Tepotinib</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Time to Reach the Maximum Plasma Concentration (tmax) of Tepotinib</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Terminal Half-Life (t1/2) of Tepotinib</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Apparent Total Body Clearance of Tepotinib From Plasma Following Oral Administration (CL/f)</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Apparent Volume of Distribution of Tepotinib During the Terminal Phase Following Extravascular Administration (VZ/f)</measure>
    <time_frame>Pre-dose up to 168 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, Stage 2: Apparent Total Body Clearance of Tepotinib From Plasma Following Oral Administration (CL/f)</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Time to Reach the Maximum Plasma Concentration (tmax) of Tepotinib</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Terminal Half-Life (t1/2) of Tepotinib</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Apparent Total Body Clearance of Tepotinib From Plasma Following Oral Administration (CL/f)</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Apparent Volume of Distribution of Tepotinib During the Terminal Phase Following Extravascular Administration (VZ/f)</measure>
    <time_frame>Pre-dose up to 168 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Time to Reach the Maximum Plasma Concentration (tmax) of Tepotinib</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Terminal Half-Life (t1/2) of Tepotinib</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Apparent Total Body Clearance of Tepotinib From Plasma Following Oral Administration (CL/f)</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Apparent Volume of Distribution of Tepotinib During the Terminal Phase Following Extravascular Administration (VZ/f)</measure>
    <time_frame>Pre-dose up to 168 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to Day 21 in Part A, B and C</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Laboratory Assessments, 12-lead Electrocardiogram (ECG) Findings and Vital Signs</measure>
    <time_frame>Baseline up to Day 21 in Part A, B and C</time_frame>
    <description>Number of participants with clinically significant changes will be reported.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A, Stage 1: First Tepotinib TF2 then TF3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Stage 1: First Tepotinib TF3 then TF2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Stage 2 (Optional): First Tepotinib TF2 then TF3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Stage 2 (Optional): First Tepotinib TF3 then TF2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: First Tepotinib TF2 Fasted then TF2 Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 under fasting conditions followed by single oral dose of Tepotinib TF2 in treatment period 2 under fed conditions. Two treatment periods will be separated by a washout period of 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: First Tepotinib TF2 Fed then TF2 Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 under fed conditions followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: First Tepotinib TF3 Fasted then TF3 Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 under fasting conditions followed by single oral dose of Tepotinib TF3 in treatment period 2 under fed conditions. Two treatment periods will be separated by a washout period of 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: First Tepotinib TF3 Fed then TF3 Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 under fed conditions followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tepotinib TF2</intervention_name>
    <description>Participants will receive single oral dose of Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.</description>
    <arm_group_label>Part A, Stage 1: First Tepotinib TF2 then TF3</arm_group_label>
    <arm_group_label>Part A, Stage 1: First Tepotinib TF3 then TF2</arm_group_label>
    <arm_group_label>Part A, Stage 2 (Optional): First Tepotinib TF2 then TF3</arm_group_label>
    <arm_group_label>Part A, Stage 2 (Optional): First Tepotinib TF3 then TF2</arm_group_label>
    <arm_group_label>Part B: First Tepotinib TF2 Fasted then TF2 Fed</arm_group_label>
    <arm_group_label>Part B: First Tepotinib TF2 Fed then TF2 Fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tepotinib TF3</intervention_name>
    <description>Participants will receive single oral dose of Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.</description>
    <arm_group_label>Part A, Stage 1: First Tepotinib TF2 then TF3</arm_group_label>
    <arm_group_label>Part A, Stage 1: First Tepotinib TF3 then TF2</arm_group_label>
    <arm_group_label>Part A, Stage 2 (Optional): First Tepotinib TF2 then TF3</arm_group_label>
    <arm_group_label>Part A, Stage 2 (Optional): First Tepotinib TF3 then TF2</arm_group_label>
    <arm_group_label>Part C: First Tepotinib TF3 Fasted then TF3 Fed</arm_group_label>
    <arm_group_label>Part C: First Tepotinib TF3 Fed then TF3 Fasted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participants of non-child bearing potential

          -  Body weight between 50 to 100 kilogram (kg)

          -  Body mass index (BMI) between 18.5 and 29.9 kilogram per meter square (kg/m^2)

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participation in a clinical study within 60 days prior to first drug administration

          -  Whole blood donation or loss of greater than 450 milliliter (mL) within 60 days prior
             to first drug administration

          -  Any surgical or medical condition, or any other significant disease that could
             interfere with the study objectives, conduct, or evaluation

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuvisan GmbH</name>
      <address>
        <city>Neu-Ulm</city>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tepotinib</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Bioequivalence</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

